Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

被引：14

作者：

Fathi, Amir T. ^{[1
]}

Chen, Yi-Bin ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Leukemia, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2014年 / 9卷 / 02期

关键词：

Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Relapse; Graft-vs.-host disease (GVHD); Emerging therapies; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; DOSE CYTOSINE-ARABINOSIDE; ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; UMBILICAL-CORD BLOOD; G-CSF CLAG; OLDER PATIENTS; MYELODYSPLASTIC SYNDROMES; LEUKOCYTE INFUSIONS;

D O I：

10.1007/s11899-014-0209-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Disease relapse remains a major cause of mortality for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Historically, patients who experience disease relapse after HSCT have a dismal prognosis with very few long-term survivors. There is no standard treatment for patients in this situation given the variability in patient characteristics, disease biology, complications such as graft-vs.-host disease (GVHD) and infections, donor availability, and patient choice. Here, we discuss the current options for treatment of relapsed AML after HSCT including conventional chemotherapy, novel agents, donor leukocyte infusion, second allogeneic HSCT, and emerging therapies.

引用

页码：186 / 192

页数：7

共 72 条

[1] MITOXANTRONE, ETOPOSIDE, AND INTERMEDIATE-DOSE CYTARABINE - AN EFFECTIVE AND TOLERABLE REGIMEN FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID-LEUKEMIA [J].

AMADORI, S ;

ARCESE, W ;

ISACCHI, G ;

MELONI, G ;

PETTI, MC ;

MONARCA, B ;

TESTI, AM ;

MANDELLI, F .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1210-1214

[2] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [J].

Attar, Eyal C. ;

Amrein, Philip C. ;

Fraser, James W. ;

Fathi, Amir T. ;

McAfee, Steven ;

Wadleigh, Martha ;

DeAngelo, Daniel J. ;

Steensma, David P. ;

Stone, Richard M. ;

Foster, Julia ;

Neuberg, Donna ;

Ballen, Karen K. .

LEUKEMIA RESEARCH, 2013, 37 (09) :1016-1020

[3] Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant [J].

Ballen, Karen K. ;

Koreth, John ;

Chen, Yi-Bin ;

Dey, Bimalangshu R. ;

Spitzer, Thomas R. .

BLOOD, 2012, 119 (09) :1972-1980

[4] Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose [J].

Bar, Merav ;

Sandmaier, Brenda M. ;

Inamoto, Yoshihiro ;

Bruno, Benedetto ;

Hari, Parameswaran ;

Chauncey, Thomas ;

Martin, Paul J. ;

Storb, Rainer ;

Maloney, David G. ;

Storer, Barry ;

Flowers, Mary E. D. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (06) :949-957

[5] Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia [J].

Becker, Pamela S. ;

Kantarjian, Hagop M. ;

Appelbaum, Frederick R. ;

Petersdorf, Stephen H. ;

Storer, Barry ;

Pierce, Sherry ;

Shan, Jianqin ;

Hendrie, Paul C. ;

Pagel, John M. ;

Shustov, Andrei R. ;

Stirewalt, Derek L. ;

Faderl, Stephan ;

Harrington, Elizabeth ;

Estey, Elihu H. .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (02) :182-189

[6] Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant [J].

Blau, IW ;

Basara, N ;

Bischoff, M ;

Günzelmann, S ;

Römer, E ;

Kirsten, D ;

Schmetzer, B ;

Kiehl, MG ;

Fauser, AA .

BONE MARROW TRANSPLANTATION, 2000, 25 (01) :41-45

[7] Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias [J].

Blum, William ;

Klisovic, Rebecca B. ;

Becker, Heiko ;

Yang, Xiaoxia ;

Rozewski, Darlene M. ;

Phelps, Mitch A. ;

Garzon, Ramiro ;

Walker, Alison ;

Chandler, Jason C. ;

Whitman, Susan P. ;

Curfman, John ;

Liu, Shujun ;

Schaaf, Larry ;

Mickle, Jon ;

Kefauver, Cheryl ;

Devine, Steven M. ;

Grever, Michael R. ;

Marcucci, Guido ;

Byrd, John C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4919-4925

[8] 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation [J].

Bolanos-Meade, Javier ;

Smith, B. Douglas ;

Gore, Steven D. ;

McDevitt, Michael A. ;

Luznik, Leo ;

Fuchs, Ephraim J. ;

Jones, Richard J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (05) :754-758

[9] Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) [J].

Bosi, A ;

Bacci, S ;

Miniero, R ;

Locatelli, F ;

Laszlo, D ;

Longo, G ;

Busca, A ;

VanLint, MT ;

DiBartolomo, P ;

Amici, A .

LEUKEMIA, 1997, 11 (03) :420-424

[10] Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies [J].

Brunner, Andrew M. ;

Kim, Haesook T. ;

Coughlin, Erin ;

Alyea, Edwin P., III ;

Armand, Philippe ;

Ballen, Karen K. ;

Cutler, Corey ;

Dey, Bimalangshu R. ;

Glotzbecker, Brett ;

Koreth, John ;

McAfee, Steven L. ;

Spitzer, Thomas R. ;

Soiffer, Robert J. ;

Antin, Joseph H. ;

Ho, Vincent T. ;

Chen, Yi-Bin .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (09) :1374-1380

← 1 2 3 4 5 6 7 8 →